An Efficacy and Safety Study of Ravulizumab in ALS Participants

Stopped The IDMC recommended the study be discontinued due to lack of efficacy with ravulizumab.

Conditions

• Amyotrophic Lateral Sclerosis
• ALS

Interventions

• DRUG: Placebo
• BIOLOGICAL: Ravulizumab

Sponsor

Alexion Pharmaceuticals, Inc.